Michael J. Huvard
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Michael J. Huvard has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
David N. Zacks
Kellogg Eye Center, University of Michigan (R.H., A.S., D.N.Z., and M.J.H.), Ann Arbor, Michigan, USA
4 shared publications- Yunshu Zhou
Department of Ophthalmology and Visual Sciences, University of Michigan, Ann Arbor, MI, USA
2 shared publications A. Hallie Lee‐Stroka
From the Department of Transfusion Medicine, Clinical Center, National Institutes of Health, Bethesda, Maryland
1 shared publicationAkbar Shakoor
Department of Ophthalmology and Visual Sciences, John Moran Eye Center, University of Utah (R.M.F., A.S., A.T.V., and C.D.C.), Salt Lake City, Utah, USA
1 shared publicationAlbert T. Vitale
Department of Ophthalmology and Visual Sciences, John Moran Eye Center, University of Utah (R.M.F., A.S., A.T.V., and C.D.C.), Salt Lake City, Utah, USA
1 shared publicationAlina K. Ba Sinha
University of Michigan Medical School, University of Michigan, Ann Arbor, Michigan
1 shared publication
Latest Publications
- 28 November 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 283, 72-80
Pathogen-Associated Visual Outcomes Following Postprocedure Endophthalmitis
- 28 November 2025
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 283, 72-80
Pathogen-Associated Visual Outcomes Following Postprocedure Endophthalmitis
- 1 May 2024
- Published by Wolters Kluwer Health in Retina
- Vol. 44 (5) , 916-922
NO EFFECT OF REAL-WORLD UNIVERSAL FACE MASKING ON POST-INTRAVITREAL INJECTION ENDOPHTHALMITIS RATE AT A SINGLE TERTIARY ACADEMIC CENTER
Purpose: To determine whether universal masking during COVID-19 altered rate and outcomes of postinjection endophthalmitis. Methods: Retrospective, single-site, comparative, cohort study. Eyes diagnosed with endophthalmitis within 4 weeks of intravitreal injection at the University of Michigan from August 1, 2012, to November 15, 2022, were identified. Cases were considered “masking” between March 15, 2020, and November 15, 2022. Endophthalmitis rate, visual acuity, and microbial spectrum were investigated. Results: There were 20 postinjection endophthalmitis cases out of 72,194 injections (0.028%; one in 3,571 injections) premasking and 10 of 38,962 with universal masking (0.026%; one in 3,846 injections; odds ratio 0.9; 95% [confidence interval]: 0.4–2.0). Referral from the community was unchanged with 32 cases referred premasking (0.35 cases/month) and 10 cases with masking (0.31 cases/month). Presenting mean the logarithm of the minimum angle of resolution visual acuity with masking of all postinjection endophthalmitis cases trended worse (2.35 ± 0.40) compared with premasking (2.09 ± 0.48; P = 0.05) with light perception visual acuity more common with masking (31.6% vs. 10.9%, P = 0.06). There was no delay in time from procedure to initial treatment (P = 0.36), no difference in the rate of initial treatment with tap and inject (T/I), and similar positive-culture rates (P = 0.77) between the cohorts. Visual acuity after 30 days of follow-up was clinically unchanged (∼20/500 vs. 20/400; P = 0.59). Conclusion: Universal masking had no effect on postinjection endophthalmitis rate or on the rate of culture-positive cases. Although presenting visual acuity appeared worse with masking, this was not statistically significant, and current treatment paradigms resulted in similar visual outcomes.
- 1 May 2024
- Published by Wolters Kluwer Health in Retina
- Vol. 44 (5) , 916-922
NO EFFECT OF REAL-WORLD UNIVERSAL FACE MASKING ON POST-INTRAVITREAL INJECTION ENDOPHTHALMITIS RATE AT A SINGLE TERTIARY ACADEMIC CENTER
Purpose: To determine whether universal masking during COVID-19 altered rate and outcomes of postinjection endophthalmitis. Methods: Retrospective, single-site, comparative, cohort study. Eyes diagnosed with endophthalmitis within 4 weeks of intravitreal injection at the University of Michigan from August 1, 2012, to November 15, 2022, were identified. Cases were considered “masking” between March 15, 2020, and November 15, 2022. Endophthalmitis rate, visual acuity, and microbial spectrum were investigated. Results: There were 20 postinjection endophthalmitis cases out of 72,194 injections (0.028%; one in 3,571 injections) premasking and 10 of 38,962 with universal masking (0.026%; one in 3,846 injections; odds ratio 0.9; 95% [confidence interval]: 0.4–2.0). Referral from the community was unchanged with 32 cases referred premasking (0.35 cases/month) and 10 cases with masking (0.31 cases/month). Presenting mean the logarithm of the minimum angle of resolution visual acuity with masking of all postinjection endophthalmitis cases trended worse (2.35 ± 0.40) compared with premasking (2.09 ± 0.48; P = 0.05) with light perception visual acuity more common with masking (31.6% vs. 10.9%, P = 0.06). There was no delay in time from procedure to initial treatment (P = 0.36), no difference in the rate of initial treatment with tap and inject (T/I), and similar positive-culture rates (P = 0.77) between the cohorts. Visual acuity after 30 days of follow-up was clinically unchanged (∼20/500 vs. 20/400; P = 0.59). Conclusion: Universal masking had no effect on postinjection endophthalmitis rate or on the rate of culture-positive cases. Although presenting visual acuity appeared worse with masking, this was not statistically significant, and current treatment paradigms resulted in similar visual outcomes.
- 14 October 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 8 (4) , 340-349
Retinal Detachments after Open-Globe Injury
- 14 October 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 8 (4) , 340-349
Retinal Detachments after Open-Globe Injury
- 19 July 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 7 (12) , 1080-1086
Clinical Characteristics and Visual Outcomes of Acute Syphilitic Posterior Placoid Chorioretinopathy
- 19 July 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 7 (12) , 1080-1086
Clinical Characteristics and Visual Outcomes of Acute Syphilitic Posterior Placoid Chorioretinopathy
- 12 August 2022
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 18 (1) , 98-100
RHEGMATOGENOUS RETINAL DETACHMENT AFTER INITIATION OF PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION 1.25% FOR TREATMENT OF PRESBYOPIA
Background/Purpose: Retinal detachment has previously been reported in association with topical miotic use for the treatment of glaucoma. Pilocarpine hydrochloride 1.25% was recently approved by the Food and Drug Administration for the treatment of presbyopia, with no reports of associated retinal detachments in the clinical trial data. Methods: Case report. Results: Two novel cases of unilateral retinal detachment occurring within 10 days of the initiation of pilocarpine 1.25% for the treatment of presbyopia were described. The patients were pseudophakic men in their 60s or 70s with preexisting retinal detachment risk factors, such as high myopia, lattice degeneration, and prior retinal detachment. Both affected eyes were treated with pars plana vitrectomy and gas endotamponade with an uncomplicated postoperative course. Conclusion: Retinal detachment may be associated with the use of pilocarpine 1.25%. Caution should be used when considering prescribing this medication in patients with preexisting retinal abnormality.
- 12 August 2022
- Published by Wolters Kluwer Health in RETINAL Cases & Brief Reports
- Vol. 18 (1) , 98-100
RHEGMATOGENOUS RETINAL DETACHMENT AFTER INITIATION OF PILOCARPINE HYDROCHLORIDE OPHTHALMIC SOLUTION 1.25% FOR TREATMENT OF PRESBYOPIA
Background/Purpose: Retinal detachment has previously been reported in association with topical miotic use for the treatment of glaucoma. Pilocarpine hydrochloride 1.25% was recently approved by the Food and Drug Administration for the treatment of presbyopia, with no reports of associated retinal detachments in the clinical trial data. Methods: Case report. Results: Two novel cases of unilateral retinal detachment occurring within 10 days of the initiation of pilocarpine 1.25% for the treatment of presbyopia were described. The patients were pseudophakic men in their 60s or 70s with preexisting retinal detachment risk factors, such as high myopia, lattice degeneration, and prior retinal detachment. Both affected eyes were treated with pars plana vitrectomy and gas endotamponade with an uncomplicated postoperative course. Conclusion: Retinal detachment may be associated with the use of pilocarpine 1.25%. Caution should be used when considering prescribing this medication in patients with preexisting retinal abnormality.
- Open Access
- 25 July 2011
- Published by Wiley in Transfusion
- Vol. 51 (12) , 2703-2708
Red blood cell preservation by droplet freezing with polyvinylpyrrolidone or sucrose‐dextrose and by bulk freezing with glycerol
BACKGROUND: Red blood cell (RBC) preservation is essential to transfusion medicine. Many blood group reference laboratories need a method to preserve rare blood samples for serologic testing at a later date. This study offers a comparison of three common cryoprotective agents and protocols used today: bulk preservation with glycerol and droplet freezing with sucrose‐dextrose (S+D) or polyvinylpyrrolidone (PVP).STUDY DESIGN AND METHODS: Human blood from 14 volunteers was collected and frozen at set intervals over 2 weeks with PVP, S+D, or glycerol. The frozen RBCs were later thawed and the percentage of surviving RBCs was determined. Detailed protocols and an instructional video are supplied.RESULTS: Over a 2‐week period, RBCs preserved with glycerol and thawed with a widely used protocol showed a recovery of 41 ± 16% (mean ± standard deviation) while those thawed with a modified glycerol protocol showed a recovery of 76 ± 8%. RBCs preserved by droplet freezing with S+D showed a recovery of 56 ± 11% while those preserved by droplet freezing with PVP showed a recovery of 85 ± 6%. Recovery values were similar with ethylenediaminetetraacetic acid or heparin anticoagulants, differing freezing rates, and varying droplet volumes.CONCLUSION: Droplet freezing with PVP offered the greatest recovery. While bulk freezing with glycerol can also be effective, droplet freezing may be a more convenient method overall. It requires less effort to thaw, needs much less storage room, and allows blood group laboratories to be frugal with thawing rare samples.
- 25 July 2011
- Published by Wiley in Transfusion
- Vol. 51 (12) , 2703-2708
Open AccessRed blood cell preservation by droplet freezing with polyvinylpyrrolidone or sucrose‐dextrose and by bulk freezing with glycerol
BACKGROUND: Red blood cell (RBC) preservation is essential to transfusion medicine. Many blood group reference laboratories need a method to preserve rare blood samples for serologic testing at a later date. This study offers a comparison of three common cryoprotective agents and protocols used today: bulk preservation with glycerol and droplet freezing with sucrose‐dextrose (S+D) or polyvinylpyrrolidone (PVP).STUDY DESIGN AND METHODS: Human blood from 14 volunteers was collected and frozen at set intervals over 2 weeks with PVP, S+D, or glycerol. The frozen RBCs were later thawed and the percentage of surviving RBCs was determined. Detailed protocols and an instructional video are supplied.RESULTS: Over a 2‐week period, RBCs preserved with glycerol and thawed with a widely used protocol showed a recovery of 41 ± 16% (mean ± standard deviation) while those thawed with a modified glycerol protocol showed a recovery of 76 ± 8%. RBCs preserved by droplet freezing with S+D showed a recovery of 56 ± 11% while those preserved by droplet freezing with PVP showed a recovery of 85 ± 6%. Recovery values were similar with ethylenediaminetetraacetic acid or heparin anticoagulants, differing freezing rates, and varying droplet volumes.CONCLUSION: Droplet freezing with PVP offered the greatest recovery. While bulk freezing with glycerol can also be effective, droplet freezing may be a more convenient method overall. It requires less effort to thaw, needs much less storage room, and allows blood group laboratories to be frugal with thawing rare samples.